Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates
Objective: The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment. Study Design: Retrospective study of neonates with thrombosis treated between January 2008 and December 2014. Re...
Gespeichert in:
| Veröffentlicht in: | Journal of perinatology 2015-10, Vol.35 (10), p.852-854 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 854 |
|---|---|
| container_issue | 10 |
| container_start_page | 852 |
| container_title | Journal of perinatology |
| container_volume | 35 |
| creator | Goldsmith, R Chan, A K Paes, B A Bhatt, M D |
| description | Objective:
The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.
Study Design:
Retrospective study of neonates with thrombosis treated between January 2008 and December 2014.
Result:
Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg
−1
, respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml
−1
) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.
Conclusion:
Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates. |
| doi_str_mv | 10.1038/jp.2015.84 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717484655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A430964045</galeid><sourcerecordid>A430964045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c583t-283a647bdd5aaed7ab89922c95509ac2a9bef2d6374a5f056fb61e12a830573c3</originalsourceid><addsrcrecordid>eNp9kl2L1TAQhoMo7nH1xh8gBUFE6THfaS-XxVVhwRu98SZM2-k5ObRJTVrW_femnlV3VSQXCTPPvDMTXkKeMrplVFRvDtOWU6a2lbxHNkwaXSolxX2yoUaKshJSn5BHKR0oXZPmITnhmlXMcL4hXy4Qkmvc4ObrAnxXJOgxP0NfoA_fYILofHG1DwMWoxsGt4swFl1Izu-KnJkijjAvEX8UzxjHwmPwMGN6TB70MCR8cnOfks8Xbz-dvy8vP777cH52WbaqEnPJKwFamqbrFAB2Bpqqrjlva6VoDS2HusGed1oYCaqnSveNZsg4VIIqI1pxSl4edacYvi6YZju61OIwQJ5kSZYZZmQltVIZff4HeghL9Hk6y4Vg-VeoNv-jspaumTJa_qZ2MKB1vg9zhHZtbc-koLWWVK4dt_-g8ulwdG3w2Lscv1Pw4lbBHmGY9ykMy-yCT3fBV0ewjSGliL2dohshXltG7eoLe5js6gtbrcM-u1lpaUbsfqE_jZCB10cg5ZTfYby1899y3wH9y72r</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716915764</pqid></control><display><type>article</type><title>Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Goldsmith, R ; Chan, A K ; Paes, B A ; Bhatt, M D</creator><creatorcontrib>Goldsmith, R ; Chan, A K ; Paes, B A ; Bhatt, M D ; Thrombosis and Hemostasis in Newborns (THiN) Group ; on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group</creatorcontrib><description>Objective:
The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.
Study Design:
Retrospective study of neonates with thrombosis treated between January 2008 and December 2014.
Result:
Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg
−1
, respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml
−1
) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.
Conclusion:
Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.</description><identifier>ISSN: 0743-8346</identifier><identifier>EISSN: 1476-5543</identifier><identifier>DOI: 10.1038/jp.2015.84</identifier><identifier>PMID: 26181722</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>692/308/409 ; 692/699/75/593 ; 692/700/1720 ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Bleeding ; Dosage ; Dosage and administration ; Dose-response relationship ; Dose-Response Relationship, Drug ; Enoxaparin ; Enoxaparin - administration & dosage ; Enoxaparin - adverse effects ; Feasibility ; Female ; Health aspects ; Humans ; Infant, Newborn ; Male ; Medicine ; Medicine & Public Health ; Neonates ; Newborn babies ; Newborn infants ; original-article ; Pediatric Surgery ; Pediatrics ; Pharmacological research ; Premature Birth ; Retrospective Studies ; Safety ; Term Birth ; Thromboembolism ; Thrombosis ; Thrombosis - drug therapy ; Treatment Outcome</subject><ispartof>Journal of perinatology, 2015-10, Vol.35 (10), p.852-854</ispartof><rights>Nature America, Inc. 2015</rights><rights>COPYRIGHT 2015 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Oct 2015</rights><rights>Nature America, Inc. 2015.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c583t-283a647bdd5aaed7ab89922c95509ac2a9bef2d6374a5f056fb61e12a830573c3</citedby><cites>FETCH-LOGICAL-c583t-283a647bdd5aaed7ab89922c95509ac2a9bef2d6374a5f056fb61e12a830573c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26181722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldsmith, R</creatorcontrib><creatorcontrib>Chan, A K</creatorcontrib><creatorcontrib>Paes, B A</creatorcontrib><creatorcontrib>Bhatt, M D</creatorcontrib><creatorcontrib>Thrombosis and Hemostasis in Newborns (THiN) Group</creatorcontrib><creatorcontrib>on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group</creatorcontrib><title>Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates</title><title>Journal of perinatology</title><addtitle>J Perinatol</addtitle><addtitle>J Perinatol</addtitle><description>Objective:
The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.
Study Design:
Retrospective study of neonates with thrombosis treated between January 2008 and December 2014.
Result:
Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg
−1
, respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml
−1
) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.
Conclusion:
Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.</description><subject>692/308/409</subject><subject>692/699/75/593</subject><subject>692/700/1720</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Bleeding</subject><subject>Dosage</subject><subject>Dosage and administration</subject><subject>Dose-response relationship</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enoxaparin</subject><subject>Enoxaparin - administration & dosage</subject><subject>Enoxaparin - adverse effects</subject><subject>Feasibility</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neonates</subject><subject>Newborn babies</subject><subject>Newborn infants</subject><subject>original-article</subject><subject>Pediatric Surgery</subject><subject>Pediatrics</subject><subject>Pharmacological research</subject><subject>Premature Birth</subject><subject>Retrospective Studies</subject><subject>Safety</subject><subject>Term Birth</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Thrombosis - drug therapy</subject><subject>Treatment Outcome</subject><issn>0743-8346</issn><issn>1476-5543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kl2L1TAQhoMo7nH1xh8gBUFE6THfaS-XxVVhwRu98SZM2-k5ObRJTVrW_femnlV3VSQXCTPPvDMTXkKeMrplVFRvDtOWU6a2lbxHNkwaXSolxX2yoUaKshJSn5BHKR0oXZPmITnhmlXMcL4hXy4Qkmvc4ObrAnxXJOgxP0NfoA_fYILofHG1DwMWoxsGt4swFl1Izu-KnJkijjAvEX8UzxjHwmPwMGN6TB70MCR8cnOfks8Xbz-dvy8vP777cH52WbaqEnPJKwFamqbrFAB2Bpqqrjlva6VoDS2HusGed1oYCaqnSveNZsg4VIIqI1pxSl4edacYvi6YZju61OIwQJ5kSZYZZmQltVIZff4HeghL9Hk6y4Vg-VeoNv-jspaumTJa_qZ2MKB1vg9zhHZtbc-koLWWVK4dt_-g8ulwdG3w2Lscv1Pw4lbBHmGY9ykMy-yCT3fBV0ewjSGliL2dohshXltG7eoLe5js6gtbrcM-u1lpaUbsfqE_jZCB10cg5ZTfYby1899y3wH9y72r</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Goldsmith, R</creator><creator>Chan, A K</creator><creator>Paes, B A</creator><creator>Bhatt, M D</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates</title><author>Goldsmith, R ; Chan, A K ; Paes, B A ; Bhatt, M D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c583t-283a647bdd5aaed7ab89922c95509ac2a9bef2d6374a5f056fb61e12a830573c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>692/308/409</topic><topic>692/699/75/593</topic><topic>692/700/1720</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Bleeding</topic><topic>Dosage</topic><topic>Dosage and administration</topic><topic>Dose-response relationship</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enoxaparin</topic><topic>Enoxaparin - administration & dosage</topic><topic>Enoxaparin - adverse effects</topic><topic>Feasibility</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neonates</topic><topic>Newborn babies</topic><topic>Newborn infants</topic><topic>original-article</topic><topic>Pediatric Surgery</topic><topic>Pediatrics</topic><topic>Pharmacological research</topic><topic>Premature Birth</topic><topic>Retrospective Studies</topic><topic>Safety</topic><topic>Term Birth</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Thrombosis - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldsmith, R</creatorcontrib><creatorcontrib>Chan, A K</creatorcontrib><creatorcontrib>Paes, B A</creatorcontrib><creatorcontrib>Bhatt, M D</creatorcontrib><creatorcontrib>Thrombosis and Hemostasis in Newborns (THiN) Group</creatorcontrib><creatorcontrib>on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of perinatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldsmith, R</au><au>Chan, A K</au><au>Paes, B A</au><au>Bhatt, M D</au><aucorp>Thrombosis and Hemostasis in Newborns (THiN) Group</aucorp><aucorp>on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates</atitle><jtitle>Journal of perinatology</jtitle><stitle>J Perinatol</stitle><addtitle>J Perinatol</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>35</volume><issue>10</issue><spage>852</spage><epage>854</epage><pages>852-854</pages><issn>0743-8346</issn><eissn>1476-5543</eissn><abstract>Objective:
The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.
Study Design:
Retrospective study of neonates with thrombosis treated between January 2008 and December 2014.
Result:
Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg
−1
, respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml
−1
) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.
Conclusion:
Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>26181722</pmid><doi>10.1038/jp.2015.84</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0743-8346 |
| ispartof | Journal of perinatology, 2015-10, Vol.35 (10), p.852-854 |
| issn | 0743-8346 1476-5543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1717484655 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 692/308/409 692/699/75/593 692/700/1720 Anticoagulants - administration & dosage Anticoagulants - adverse effects Bleeding Dosage Dosage and administration Dose-response relationship Dose-Response Relationship, Drug Enoxaparin Enoxaparin - administration & dosage Enoxaparin - adverse effects Feasibility Female Health aspects Humans Infant, Newborn Male Medicine Medicine & Public Health Neonates Newborn babies Newborn infants original-article Pediatric Surgery Pediatrics Pharmacological research Premature Birth Retrospective Studies Safety Term Birth Thromboembolism Thrombosis Thrombosis - drug therapy Treatment Outcome |
| title | Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A29%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20and%20safety%20of%20enoxaparin%20whole%20milligram%20dosing%20in%20premature%20and%20term%20neonates&rft.jtitle=Journal%20of%20perinatology&rft.au=Goldsmith,%20R&rft.aucorp=Thrombosis%20and%20Hemostasis%20in%20Newborns%20(THiN)%20Group&rft.date=2015-10-01&rft.volume=35&rft.issue=10&rft.spage=852&rft.epage=854&rft.pages=852-854&rft.issn=0743-8346&rft.eissn=1476-5543&rft_id=info:doi/10.1038/jp.2015.84&rft_dat=%3Cgale_proqu%3EA430964045%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716915764&rft_id=info:pmid/26181722&rft_galeid=A430964045&rfr_iscdi=true |